CMV Immunity Monitoring in Lung Transplant Recipients
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and feasibility of using a laboratory
test to guide duration of antiviral prophylaxis with valganciclovir (medication used to
prevent viral infections) after lung transplant. The laboratory test, inSIGHT™ CMV T Cell
Immunity Panel, measures patients' immune response to a common viral infection known as
cytomegalovirus (CMV). The goal of this study will be to safely decrease how long patients
need to take valganciclovir based on the results of the CMV T Cell Immunity Panel.